Oragenics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 14.29 million compared to USD 15.71 million a year ago. Basic loss per share from continuing operations was USD 7.11 compared to USD 8.09 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.33 USD | +42.07% | +26.63% | -58.59% |
May. 16 | Sector Update: Health Care Stocks Ease Thursday Afternoon | MT |
May. 16 | Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise | MT |
1st Jan change | Capi. | |
---|---|---|
-58.59% | 10.44M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- OGEN Stock
- News Oragenics, Inc.
- Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022